Tempus AI Stock Price, News & Analysis

Tempus (NASDAQ:TEM) announced six abstracts accepted for presentation at ESMO Congress 2025 (Oct 17–21, 2025) in Berlin: two oral presentations and four posters.

Key highlights include an OPTIC RCC phase II RNAseq‑guided cohort (26 angiogenic patients; 21 with post‑baseline scans: 100% tumor burden reduction; RECIST: 71% partial response, 29% stable disease) and a 425‑patient analysis linking LAG3 RNA expression to immunotherapy objective response rates in mRCC. Other posters report real‑world immunogenomic and biomarker findings across prostate, NSCLC, biliary tract, and integrin beta‑6 research using Tempus de‑identified data and Lens analytics.

Tempus (NASDAQ: TEM) was selected by the Advanced Research Projects Agency for Health (ARPA-H) on October 9, 2025 to provide CRO and testing services for the ADAPT program, which targets adaptive precision therapies for metastatic non-small cell lung, breast, and colorectal cancers.

Tempus will supply its AI-enabled diagnostics (xE, xR, xF+, xM), use its Compass CRO to manage trial operations across sites, and perform data integration and harmonization for the study to support early detection of tumor resistance and dynamic treatment adjustments.

Ambry Genetics, a subsidiary of Tempus AI (NASDAQ: TEM), has announced significant improvements to its Ambry CARE Program®, enhancing breast cancer risk assessment capabilities. The update integrates breast density measurements into the Tyrer-Cuzick (TC) scoring system within electronic health records (EHR), enabling more accurate risk assessments.

The enhanced platform addresses a critical healthcare gap, as 93% of high-risk women who qualify for breast MRI screening currently don't receive it. The system now includes four TC score options aligned with BI-RADS breast density categories (A-D), helping clinicians identify patients with a 20% or higher risk who may need increased screening. A recent study in the Journal of the National Comprehensive Cancer Network validated CARE's accuracy, demonstrating 99.5% accuracy in interpreting NCCN Guidelines®.

Tempus AI (NASDAQ: TEM) has received FDA 510(k) clearance for its RNA-based Tempus xR IVD device, a next-generation sequencing diagnostic tool for cancer research. The device analyzes RNA from tumor tissue specimens to detect gene rearrangements in solid malignant neoplasms.

The xR IVD assay will serve as a life sciences tool to support drug development programs, enabling more precise patient selection for clinical trials and personalized cancer treatments. The technology uses targeted high-throughput hybridization-based capture technology and is designed for use by qualified healthcare professionals in accordance with oncology guidelines.

Renalytix (OTCQB: RNLXY) has partnered with Tempus AI (NASDAQ: TEM) to expand the availability of its FDA-approved kidneyintelX.dkd prognostic blood test. The test helps predict risk levels for kidney function decline in patients with type 2 diabetes and chronic kidney disease stages 1-3b, affecting nearly 15 million individuals in the US.

The collaboration leverages Tempus's extensive clinical network and AI-enabled platform to integrate kidneyintelX.dkd testing into existing clinical workflows. The test will be processed in Renalytix's laboratory, with results reported electronically to clinicians and patient portals, enabling timely interventions to improve diabetes and kidney care outcomes.

Tempus (NASDAQ: TEM) has received FDA 510(k) clearance for its updated Tempus Pixel cardiac imaging platform. The enhanced AI-powered device now generates T1 and T2 inline maps for cardiac MR image analysis, enabling precise numerical values for tissue characteristics and detection of conditions like fibrosis, inflammation, and edema.

The platform provides advanced viewing and automated reporting capabilities, improving efficiency in flow visualization, functional analysis, and tissue characterization. Notably, Tempus Pixel can generate these maps directly from raw MRI data, even when the scanner cannot produce them natively.

This development follows Tempus's strategic acquisitions, including Arterys in 2022 and Paige, which added AI-powered imaging tools and a dataset of nearly 7 million clinically annotated pathology slides to Tempus's precision medicine platform.

Tempus (NASDAQ: TEM) has published a significant study in JCO Precision Oncology validating their PurIST® algorithm for pancreatic cancer treatment selection. The study, analyzing 931 patients with advanced pancreatic ductal adenocarcinoma (PDAC), demonstrates PurIST's effectiveness in guiding first-line chemotherapy choices.

The algorithm classifies PDAC tumors into "classical" or "basal" subtypes, showing that classical subtype patients treated with FOLFIRINOX achieved a median overall survival of 11.8 months versus 7.0 months for basal subtype patients. Notably, classical subtype patients with good performance status showed a 33% reduced risk of death when treated with FOLFIRINOX compared to alternative therapy.

Tempus (NASDAQ: TEM) and Northwestern Medicine announced a significant expansion of their partnership, making Northwestern Medicine the first health system to integrate David, Tempus' generative AI clinical co-pilot, into its electronic health record (EHR) platform.

The integration will enable Northwestern Medicine's clinical teams to build custom AI agents, query patient data using natural language, automate pre-appointment preparation, receive real-time support during appointments, and streamline post-appointment tasks. This collaboration builds on their decade-long partnership in data-driven healthcare.

The implementation aims to enhance care delivery by providing physicians with real-time, AI-enabled insights and reducing administrative burden while improving patient outcomes.

Tempus AI (NASDAQ: TEM), an AI-driven precision medicine technology company, announced its participation in Morgan Stanley's 23rd Annual Global Healthcare Conference in New York City from September 8-10, 2025. Founder and CEO Eric Lefkofsky and CFO Jim Rogers will engage in a fireside chat on September 8 from 1:05 to 1:40 p.m. EST. The discussion will be accessible via live audio webcast.